03:09 PM EDT, 08/27/2025 (MT Newswires) -- (Updates with stock movement in headline, first paragraph)

BioXcel Therapeutics ( BTAI ) shares were down over 22% in recent Wednesday trading even after the firm said a late-stage safety trial of BXCL501 met its at-home's primary endpoint.

The firm said the trial met its primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia.

The results showed no discontinuations due to tolerability in the BXCL501 arm, BioXcel said.

The trial data will form the basis of the supplemental new drug application submission for label expansion of Igalmi in the at-home setting planned for Q1 2026.

Price: 4.05, Change: -1.20, Percent Change: -22.81